About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

'Shock and Kill' Approach to Eliminating HIV Challenged

by Anjali Aryamvally on May 2, 2018 at 5:19 PM
Font : A-A+

'Shock and Kill' Approach to Eliminating HIV Challenged

Study sheds new insights into the cellular processes behind the 'shock and kill' approach to curing HIV, which the research team say challenges the effectiveness of the treatment.

The study, published in the journal eLife, suggests the need to explore alternative treatment strategies against HIV - a virus which 36.7 million people globally were living with in 2016, with 1.8 million people becoming newly infected in the same year, according to figures from UNAIDS*.

Advertisement


HIV is currently incurable, due to the persistence of latently infected cells - cells that host the dormant virus. The 'shock and kill' approach to treating the infection involves using latency-reversing agents (LRAs) to force the infected cells to produce HIV again (the 'shock' phase), while maintaining antiretroviral therapy (ART) to prevent the occurrence of new infections. This reactivation of HIV would cause the shocked cells to be killed directly or indirectly by ART (otherwise known as the 'kill' phase).

However, currently available LRAs have proven ineffective. A team of researchers from the Buck Institute for Research on Aging set out to understand why. "Several obstacles can explain the failure of LRAs, but the biggest challenge to date is our inability to accurately identify the number of cells in the HIV latent reservoir - the group of cells that are infected with HIV but do not produce new infections," says lead author Emilie Battivelli, Postdoctoral Research Scholar at the Buck Institute.
Advertisement

To address this challenge, Battivelli developed a new dual-fluorescence HIV-1 reporter virus, HIVGKO, to investigate the ability of various LRAs to reactivate HIV infection in latent cells. This virus encodes two different fluorescent proteins, GFP and mKO2. GFP is under the control of the HIV promoter and reveals the state of HIV transcription (latency versus productive), while mKO2 is under the control of a separate promoter (EF1alpha) and allows the identification of cells that are infected (latent and productive).

Using this reporter, the scientists discovered that a remarkably small number (less than 5%) of latently infected cells are reactivated by LRAs. Next, they carried out sequencing analysis of reactivatable versus non-reactivatable HIV infection in latent cell populations. This revealed that the sites where the virus integrates into the genome are distinguishable between viruses that reactivate and those that do not in response to LRAs.

"Together, these results indicate that while 'shock and kill' might be helpful in reactivating and possibly eliminating a small subset of highly reactivatable latent HIV genomes, other approaches will be necessary to control or eliminate the less readily reactivatable population identified both here and in patients," says senior author Eric Verdin, President and CEO of the Buck Institute.

"Perhaps this cell population should instead be 'blocked and locked' using latency-promoting agents, as previous research has suggested. For a functional cure, having non-reactivatable latent HIV genomes would surely be preferable to a lifetime of chronic active infection."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Menstrual Disorders
Coffee May Help You Fight Endometrial Cancer
Fermented Skin Care
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Oral Health And AIDS AIDS/HIV AIDS/HIV - Epidemiology AIDS/HIV - Clinical Features AIDS/HIV - Health Education AIDS/HIV - Prevention And Transmission AIDS / HIV - Treatment AIDS/HIV- Lab Tests and Faqs Prostitution: Fresh Stakes in the Oldest Trade HIV Symptom 

Recommended Reading
Circumcision in Boys can Prevent HIV in Africa
Peers can influence more boys and young men who are in the age group of 10 and 19 years to be ......
Adopting a New HIV Regimen Likely to Help India Tackle HIV
Adoption of dolutegravir-based regimen could be cost-effective, even cost-saving, over the long ......
New Mechanism shows How HIV evades Immune System
The mechanism of HIV invasion into the immune system has been identified. Also, HIV disables a ......
New Way to Fight HIV Transmission Developed
New way to protect women from HIV infection has been devised by University of Waterloo researchers....
AIDS / HIV - Treatment
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV...
AIDS/HIV
"AIDS is an epidemic disease, a potentially preventable, deadly infection for which there is no cure...
AIDS/HIV - Clinical Features
Encyclopedia section of medindia gives general info about HIV Clinical Features...
AIDS/HIV - Epidemiology
AIDS or HIV is an epidemic disease, a potentially deadly infection that can be prevented with preca...
AIDS/HIV - Health Education
Encyclopedia section of medindia gives general info about AIDS information and health education....
AIDS/HIV - Prevention And Transmission
Encyclopedia section of medindia explains in brief about the prevention for AIDS/HIV...
Oral Health And AIDS
AIDS has taken on massive proportions in modern times. It is estimated that over 15 million people a...
Prostitution: Fresh Stakes in the Oldest Trade
Prostitution has broadened its base to include street prostitution, massage brothels, gigolo outcall...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT A DOCTOR
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)